Lakefront Biotherapeutics | GLPG - Net Income


Lakefront Biotherapeutics reported EUR14.49M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
argenx SE USD 472M 106M Jun/2026
AstraZeneca USD 2.51B 573M Jun/2026
Biogen USD 97.5M 222M Jun/2026
Genmab DKK 31M 370M Dec/2025
Gilead Sciences USD -10.5B 12.52B Jun/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
GRIFOLS EUR 154M 81M Jun/2026
Hikma Pharmaceutical USD 164M 45M Dec/2025
Incyte USD 585.6M 282.27M Jun/2026
Merck EUR 659M 340M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sanofi EUR 343M 1.27B Jun/2026
UCB EUR 1.08B 608M Dec/2025
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026